Brookline Capital Upgrades Verrica Pharmaceuticals to Buy, Announces $17 Price Target

Benzinga · 2d ago
Brookline Capital analyst Kemp Dolliver upgrades Verrica Pharmaceuticals (NASDAQ:VRCA) from Hold to Buy and announces $17 price target.